Trial Profile
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms NOR-SWITCH
- 24 Oct 2018 Results investigating immunogenicity of infliximab, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 31 Aug 2018 Biomarkers information updated
- 16 Jun 2018 Results evaluating the consistency and fine specificity of anti-drug antibody (ADAb) responses to INX and CT P13, in arthritis and IBD patients, after switching from INX to CT P13 presented at the 19th Annual Congress of the European League Against Rheumatism